

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): Acton, Susan L.

For: NOVEL PROTEIN KINASE MOLECULES AND USES THEREFOR

thereon prior to mailing. 37 C.F.R. Section 1.10(b).

1. Type of Application

*WARNING:

This no	ew applie	cation is for a(n)		
	()	Original (nonprovisional)		
	()	Design		
	()	Plant		
	(X)	Divisional		
	()	Continuation		
	()	Continuation-in-part (C-I-P)		
		CERTIFICATION UNDER 37 C.F	F.R. SI	ECTIONS 1.8(a) and 1.10*
I hereby	certify tha	at, on the date shown below, this correspondence	e is be	ing:
		MAIL	ING	
X		d with the United States Postal Service in an envisioner for Patents, P.O. Box 1450, Alexandria,		
		C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*
	with suff	ficient postage as first class mail.	X	
		MID A NICES		Mailing Label No. EV439625520US
	transmitt	TRANSM ted by facsimile to the Patent and Trademark Of		Sia Stranger
			Sig	gnature
Date: Fe	ebruary 25	5, 2004	<u>Se</u>	an Hunziker
			(tr	ype or print name of person certifying)

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed

"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement

will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page I of 6)

- 2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)
 - [X] The new application being transmitted is a divisional application of U.S. Application Serial No. 09/757,982, filed January 10, 2001, which is a divisional of U.S. Application Serial No. 09/163,115, filed September 29, 1998, which claims the benefit of prior U.S. Provisional Application No. 60/099,657, filed September 9, 1998.

3	Maintenance	of Copendency	of Prior	Annlication
J.	Maintenance	or Cobellaelicv	OF LLIOL Y	Application

A.	()	Extension of time in prior application
B.	()	Conditional Petition for Extension of Time in Prior Application (complete this item, if previous item not applicable)
	()	A conditional petition for extension of time is being filed in the pending prior application.
		[] A copy of the conditional petition filed in the prior application is attached.

4. Abandonment of Prior Application (if applicable)

[] Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

Notification in Parent Application of This Filing

[] A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

5. Papers Enclosed

Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

- 118 Pages of Specification, including
 - 79 Pages of Description
 - 32 Pages of Sequence Listing
 - 6 Pages of Claims
 - 1 Page of Abstract
- 11 Sheets of Drawings (Figures 1-5)

	The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO
•	ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
(X)	Formal
()	Informal

6.	Additional Papers Enclosed				
	(x) (x) ()	Information Disclosure Statement (37 C.F.R. Section 1.98) (2 pages) Form PTO-1449 (PTO/SB/08A and 08B) (4 pages) Citations			
	(X)	4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence			
	[]	Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments			
	[X]	Other: Preliminary Amendment (10 pages)			
7.	Declaration or Oath (including power of attorney)				
	(X)	(3 pages) Copy of the executed Declaration and Power of Attorney document filed in prior U.S. Application Serial No. 09/757,982.			
	(X)	(2 pages) Copy of Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney document filed in prior U.S. Application Serial No. 09/757,982.			
8.	Assignment				
	[X]	Assignment of the invention from the inventor (Susan L. Acton) to Millennium Pharmaceuticals, Inc., filed in prior U.S. Application Serial No. 09/757,982, and recorded on February 16, 1999, at Reel 9762, Frame 0552			
		() is enclosed. (X) will follow.			



- 9. Fee Calculation (37 C.F.R. Section 1.16)
 - A. (x) Regular application

		CLAIMS AS F	ILED		
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
Total Claims (37 C.F.R. Section 1.16(c))	22	- 20 =	2	\$18.00	\$36.00
Independent Claims (37 C.F.R. Section 1.16(b))	2	- 3 =	0	\$86.00	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$290.00			\$0.00

Filing Fee Calculation

\$806.00

()	Amendment canceling extra claims is enclosed.
[]	Amendment deleting multiple-dependencies is enclosed
()	Fee for extra claims is not being paid at this time.

10.	Metho	Method of Payment of Fees					
	()	Check in the amount of \$					
	(X) Charge Account No. 501668 in the amount of A duplicate of this transmittal is attached.						
11.	Authorization to Charge Additional Fees [X] The Commissioner is hereby authorized to charge the following additional fees by paper and during the entire pendency of this application to Account No. 501668.						
		(X)	37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)				
		[X]	37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)				
		()	37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)				
		()	37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a).				
		()	37 C.F.R. Section 1.17 (application processing fees)				
		()	37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance pursuant to 37 C.F.R. Section 1.311(b))				
12.	Instru [X]		as to Overpayment it Account No. 501668.				
	()	Refu	nd				

13. Correspondence Address

Direct all future correspondence to:

Customer Number 30405 OR

Intellectual Property Department MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street Cambridge, MA 02139

February 25, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat Registration No. 50,609 40 Landsdowne Street Cambridge, MA 02139 Telephone - (617) 374-7679 Facsimile – (617) 551-8820

(X) **Statement Where No Further Pages Added**

> This transmittal ends with this page. [X]